Skip to main content

Too Often, Overdose Survivors Miss Out on Vital Treatments: Study

Medically reviewed by Carmen Pope, BPharm. Last updated on June 19, 2024.

By Dennis Thompson HealthDay Reporter

WEDNESDAY, June 19, 2024 -- Most seniors who survive a drug overdose often miss out on treatments that could help save them from a subsequent OD, a new study shows.

Almost 24,000 Medicaid beneficiaries died from a follow-up overdose out of 137,000 who survived an OD in 2020, researchers say. That’s nearly one in five (17%).

“People who have experienced one overdose are more likely to experience another,” said Miriam Delphin-Rittmon, assistant secretary for mental health and substance use at the U.S. Department of Health and Human Services.

However, treatment can reduce their risk. The odds of dying from another OD were:

“We found that when survivors received gold-standard care such as medications for opioid use disorder and naloxone, the chances of dying from an overdose in the following year drop dramatically,” Delphin-Rittmon said. “In short, medications for opioid use disorder, opioid overdose reversal medications and behavioral health supports save lives.”

Unfortunately, only 4% of the group received drugs like methadone and buprenorphine to treat opioid addiction, while only 6% filled a prescription for naloxone, which blunts the effect of opioids.

What’s more, patients had to wait nearly two and a half months (72 days) to receive their medication after surviving an overdose, results show.

Overall, nine out of 10 (89%) beneficiaries received behavioral health services within the year following their overdose, with an average of 15 days of treatment during the year.

The new study was published June 17 in the journal JAMA Internal Medicine.

“These findings underscore the importance of high-quality care following an overdose, and the opportunities that remain to connect people with needed care,” said Dr. Dora Hughes, acting chief medical officer for the U.S. Centers for Medicare and Medicaid Services. “Increasing the number of beneficiaries accessing these medications in a timely manner will save lives.”

The results add to a growing body of evidence indicating that known methods of warding off fatal overdoses are rarely incorporated into the care of people struggling with opioid addiction, researchers concluded.

“At a time when over 100,000 people continue to die each year from overdose, we must prioritize making effective treatments and tools accessible – especially to those who are at the highest risk,” said Dr. Nora Volkow, director of the National Institute on Drug Abuse (NIDA).

“Connecting with someone in an emergency department or after they have experienced a nonfatal overdose provides a valuable opportunity to both support them acutely in that moment, as well as offer lifesaving tools that can protect them from future overdoses, link them into treatment, and foster recovery,” Volkow added in a NIDA news release.

Sources

  • National Institute on Drug Abuse, news release, June 17, 2024

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Supreme Court Rejects Purdue Pharma Opioid Settlement

FRIDAY, June 28, 2024 -- The U.S. Supreme Court on Thursday struck down a controversial settlement that drug maker Purdue Pharma had reached with victims of the opioid...

Only 1 in 4 People Who Need Meds to Fight Opioid Addiction Get Them

THURSDAY, June 27, 2024 -- Just 25% of people battling opioid use disorder are getting medications aimed at helping them quit and potentially avoid an overdose, new data...

Magic Mushroom's Psilocybin Is America's Most Popular Hallucinogen

THURSDAY, June 27, 2024 -- As psilocybin mushrooms become the most popular psychedelic in the United States, some states have started to ease regulations on its recreational...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.